NDLI: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Content Provider	Springer Nature : BioMed Central
Author	Martin, Greg Brunkhorst, Frank M Janes, Jonathan M Reinhart, Konrad Sundin, David P Garnett, Kassandra Beale, Richard
Abstract	Introduction Since the launch of drotrecogin alfa activated (DrotAA), institutions and individual countries have published data on its use in clinical practice, based on audit or registry data. These studies were limited in size and geographic locale and included patients with greater disease severity and higher mortality than those in clinical trials. The purpose of this study was to compare baseline characteristics and clinical outcomes (using appropriate statistical adjustments) of patients treated or not treated with DrotAA from the international PROGRESS (Promoting Global Research Excellence in Severe Sepsis) cohort study of severe sepsis. Methods PROGRESS was a global, non-interventional, multi-center, prospective, observational study of patients having a diagnosis of severe sepsis treated in intensive care units at a participating institution. All treatment modalities were as per standard of care at the participating institutions. Baseline characteristics and hospital mortality were analyzed and regression techniques used to develop propensity and outcome models adjusted for baseline imbalances between groups. Results Overall, 14,543 patients from 37 countries were enrolled and 12,492 had complete data for analysis. Germany was the highest enrolling country (1,810; 14.5%) and the US had the most DrotAA patients (206, 23.3%); 882 (7%) overall received DrotAA therapy. DrotAA-treated patients were younger (median age 58 vs. 61 years), had greater organ dysfunction (cardiovascular: 90% vs. 74%; respiratory: 90% vs. 81%; renal: 60% vs. 45%; metabolic: 63% versus 42%; 3 or more organ dysfunctions: 84% vs. 67%) and had a higher median APACHE II score (26 vs. 23, all with P < 0.001). Although in-hospital mortality was similar for DrotAA and non-DrotAA-treated patients (49.6% vs. 49.7%, respectively), after adjusting for imbalances, patients receiving DrotAA had a 28% (0.60 to 0.86, 95% Confidence Intervals) reduction in the odds of death and a relative risk reduction of 17% (P = 0.0003). Conclusions In the PROGRESS registry, DrotAA-treated patients were younger, more severely ill, and had fewer co-morbidities than patients not treated with DrotAA. After adjustment for group differences, a significant reduction in the odds of death was observed for patients that received DrotAA compared with those that did not.
Related Links	https://ccforum.biomedcentral.com/counter/pdf/10.1186/cc7936.pdf
Ending Page	14
Page Count	14
Starting Page	1
File Format	HTM / HTML
ISSN	13648535
DOI	10.1186/cc7936
Journal	Critical Care
Issue Number	3
Volume Number	13
Language	English
Publisher	BioMed Central
Publisher Date	2009-06-30
Access Restriction	Open
Subject Keyword	Intensive Critical Care Medicine Emergency Medicine Severe Sepsis Additional Data File Relative Risk Reduction Survive Sepsis Campaign Drotrecogin Alfa
Content Type	Text
Resource Type	Article
Subject	Critical Care and Intensive Care Medicine
Journal Impact Factor	8.8/2023
5-Year Journal Impact Factor	10.4/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry

Drotrecogin alfa (activated): real-life use and outcomes for the UK

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Sepsis: drotrecogin alfa (activated) use and patient outcomes.

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death

The safety profile of drotrecogin alfa (activated)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Similar Documents

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry

Drotrecogin alfa (activated): real-life use and outcomes for the UK

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Sepsis: drotrecogin alfa (activated) use and patient outcomes.

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death

The safety profile of drotrecogin alfa (activated)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes